Just responding quickly, but not completely:
“1. Why NWBO ever received any help from any funds cancer organizations? After having Clinical trials at prestigious UCLA and treatment has saved some lives. They would have been a contribution in terms of funds from the cancer community.
Actually, UCLA has trials sponsored by NIH and other cancer related charities using the DCVax equivalent that they refer to in their scholarly articles. NIH is a part owner on certain DCVax related patents. A major charity had been involved in the U.K. in promoting and cheerleading with regulators the benefits of DCVax, I presume based upon the enthusiasm of patients and doctors in the U.K.. I’m not going to look it all up for you now but maybe some others will be kind enough to provide the links.
“2. Why LP didn't establish a partner? it looks like her solo fight”
I think they have considered it but probably the offers were low balled. Cancer vaccines have notoriously failed numerous times and the race to become the NWBO partner were not as competitive as for Car-T applications which were subject to a bubble and bidding wars. I think she also wanted to be sure it would get to market and not get shelved, which could happen when you sell out to some large Pharma orgs, if you sign-up too early. I think this is especially true if a treatment might deeply affect the commercial value of other very valuable assets.
“3. Why this was not considered for EAU or Right to try? I am really wondering John Mccain would have tried this?”
This is not an emergency (EAU) and right to try laws are terrible for tiny biotechs. All of the ones I am in have foreclosed participating in that specific program. The FDA has always allowed direct application to get drugs separate from that program and I think some patients may have gone that route, others, not knowing how fairly easy it is, have been discouraged. But at the end of the day, someone has to pay, and making one-off vaccines occasionally is not a commercial enterprise. It’s potentially a massive diversion of spare funds that likely costs many times what would be a realistic price for the treatment. I also do not recall leukemia patients using such options “right to try” for Car-T therapies, and I do not recall any of the companies I invested in ever going the EAU route. That’s really been popularized as an option by COVID19, which actually is an emergency.
“Also, I want to mention is that the SP is depressing, keeping in view of 10 year TLD on the horizon. We need serious interest from the investor community. Day traders are selling by just 2-3 cents rise each time.”
Happens a lot with depressed microcap biotechs. They are not for newbies or the feint hearted. The price could explode on good trial result news or continue to be abused until other validation events. You really never know. Tiny companies on the OTC should not be bought without some understanding of the risks, particularly with regard to price manipulation by market makers and others.
News 
Market Data 
Discover 
AI
